A Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Acute Exacerbation of Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06134063
• Other study ID #: XFBD-AECOPD-001
• Status: Recruiting
• Phase: N/A
• Start date: November 2023
• Est. completion date: March 2025

Study information

• Verified date: November 2023
• Source: Peking University People's Hospital
• Contact: Jingli Feng
• Phone: 18810535368
• Email: 20210941147[@]bucm.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective,multicenter, randomized, double-blind, placebo-controlled trial.

This study plans to enroll 375 participants who will be randomly assigned in a 2:1 ratio. On the basis of basic treatment, one group will receive Xuanfei Baidu granule, while the other group will receive Xuanfei Baidu granule placebo, with one sachet in the morning and one in the evening, for a duration of 7 days. Visits will be conducted on days 7, 14, and 21 after enrollment.

If any participant experiences an acute exacerbation of chronic obstructive pulmonary disease (COPD) requiring hospitalization during the treatment period, they will continue taking the medication until the 7-day course is completed. In case of a COPD exacerbation hospitalization event during the study, hospital admission date, duration of hospitalization, and the treatment regimen during hospitalization will be recorded.

Description:

This study is a prospective,multicenter, randomized, double-blind, placebo-controlled trial.

This study plans to enroll 375 participants who will be randomly assigned in a 2:1 ratio. On the basis of basic treatment, one group will receive Xuanfei Baidu granule, while the other group will receive Xuanfei Baidu granule placebo, with one sachet in the morning and one in the evening, for a duration of 7 days. Visits will be conducted on days 7, 14, and 21 after enrollment.

If any participant experiences an acute exacerbation of chronic obstructive pulmonary disease (COPD) requiring hospitalization during the treatment period, they will continue taking the medication until the 7-day course is completed. In case of a COPD exacerbation hospitalization event during the study, hospital admission date, duration of hospitalization, and the treatment regimen during hospitalization will be recorded.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 375
• Est. completion date: March 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Aged between 40 and 80 years old, including 40 and 80 years old, regardless of gender;

• Clinical records of traceable of the chronic obstructive pulmonary disease history records, after bronchodilator FEV1 less than 80% of the expected value;

• Comply with the definition of COPD acute exacerbations and with mild and moderate severity assessment;

• Symptoms of AECOPD time less than 48 h;

• "Shiduyufei" diagnostic standard;

• Volunteered for the study, signed informed consent, is willing to cooperate with the visitor.

Exclusion Criteria:

• Patients showing signs of hospitalization;

• With respiratory system diseases other than the AECOPD (for example, pneumonia, bronchiectasis, active tuberculosis, pneumothorax, pleural effusion, pulmonary embolism, or affect the respiratory movement function of neuromuscular diseases, etc.);

• Patients with severe basic diseases (for example, uncontrolled hypertension diabetes and complicated with heart failure (NYHA class IV), severe arrhythmia, acute coronary syndrome, hemodynamic instability, long-term use of immunosuppressive agents, etc.);

• With primary disease such as tumor or blood system;

• With severe liver disease (cirrhosis, portal hypertension, varices bleeding) or renal insufficiency;

• Pregnant women and breastfeeding mothers, those suspected of being pregnant, or women of childbearing age at risk of pregnancy who have not taken effective contraceptive measures;

• Dementia, mental disorders, such as unable to read or understand the research content, the information collection;

• With drug allergy;

• 3 months prior to screening for other interventional clinical research and the research data information;

• Within 1 week before screening been oral Chinese medicine or other proprietary Chinese medicine treatment;

• Patient refused to sign a consent form, or estimate adherence is poor, or follow-up possibilities is poor.

Related Conditions & MeSH terms

• Acute Exacerbation of Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Xuanfei Baidu granule
Xuanfei Baidu granule will be administered twice daily for 7 days on the basis of basic treatment
• Xuanfei Baidu granule Placebo
Xuanfei Baidu granule Placebo will be administered twice daily for 7 days on the basis of basic treatment

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment failure rate.	Admission for acute exacerbation of COPD within 21 days after enrollment (excluding admission for reimbursement).	within 21 days after enrollment
Secondary	Duration of acute exacerbation of COPD in this episode.	Duration of acute exacerbation of COPD in this episode.	within 21 days after enrollment
Secondary	Change in the Dyspnea Visual Analog Scale (VAS) score after treatment compared to baseline: Assessing the severity of breathlessness on days 7, 14, and 21 after enrollment.	The minimum and maximum values for VAS scores are 0 and 10. A higher score indicates a worse outcome.	days 7, 14, and 21 after enrollment
Secondary	Change in the COPD Assessment Test (CAT) score after treatment compared to baseline: Assessing the degree of health impairment on days 7, 14, and 21 after enrollment.	The CAT score ranges from 0 to 40. Patients scoring 0 to 10 points are classified as having "mild impact" of COPD, 11 to 20 points as "moderate impact," 21 to 30 points as "severe impact," and 31 to 40 points as "very severe impact.	on days 7, 14, and 21 after enrollment
Secondary	Change in the mMRC score after treatment compared to baseline: Assessing the severity of breathlessness on days 7, 14, and 21 after enrollment.	The minimum and maximum values for mMRC scores are 0 and 4. A higher score indicates a worse outcome.; Grade 0 means I only get breathless with strenuous exercise; Grade 1 means I get short of breath when hurrying on the level or walking up a slight hill; Grade 2 means I walk slower than people of the same age on the level because of breathlessness, or I have to stop for rest when walking at my own pace on the level; Grade 3 means I stop for breath after walking about 100 meters or after a few minutes on the level; Grade 4 means I am too breathless to leave the house or I am breathless when dressing or undressing.	on days 7, 14, and 21 after enrollment
Secondary	Change in the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) score after treatment compared to baseline: Assessing daily COPD exacerbation events within 21 days after enrollment.	The minimum and maximum values for EXACT scores are 0 and 70. A higher score indicates a worse outcome.	within 21 days after enrollment
Secondary	Change in the Clinical Symptom Score after treatment compared to baseline: Observing clinical symptom scores on days 7, 14, and 21 after enrollment.	The clinical symptom score is based on the individual symptoms of the patient graded as none, mild, moderate, or severe, with scores of 0, 1, 2, and 3, respectively. The scores for each individual symptom are then added up to obtain the total score, ranging from a minimum of 0 to a maximum of 27. A higher total score indicates a more severe outcome.	on days 7, 14, and 21 after enrollment
Secondary	Incidence of clinical abnormalities in laboratory examination and electrocardiogram.	Incidence of clinical abnormalities in laboratory examination and electrocardiogram.	within 21 days after enrollment
Secondary	Incidence of adverse events and serious adverse events.	Incidence of adverse events and serious adverse events.	within 21 days after enrollment